Nosocomial or hospital-acquired infections are associated with prolonged hospitalizations and increased healthcare costs. Infections associated with surgical implants are becoming more difficult and more costly to manage, as they require repeated surgical procedures and a longer period of time to treat patients. Continued advances in the use of medical devices, an increase in the number of immunocompromised patients, and a steady rise in the prevalence of antibiotic-resistant organisms has renewed interest in the development of novel therapies that can be used to prevent and treat nosocomial infections. This review provides an overview of bacterial adhesins and focuses on novel immunological therapies developed to treat staphylococcal infections.
HoranT.C., CulverD.H., GaynesR.P., JarvisW.R., EdwardsJ.R., ReidC.R.Nosocomial infections in surgical patients in the United States, January 1986–June 1992. National Nosocomial Infections Surveillance (NNIS) System. Infect Control Hosp Epidemiol1993; 14: 73–80.
2.
WhitehouseJ.D., FriedmanN.D., KirklandK.B., RichardsonW.J., SextonD.J.The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: Adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol2002; 23: 183–9.
3.
DarouicheR.O.Device-associated infections: A macro-problem that starts with microadherence. Clin Infect Dis2001; 33: 1567–72.
4.
CabellC.H., HeidenreichP.A., ChuV.H.Increasing rates of cardiac device infections among Medicare beneficiaries: 1990-1999. Am Heart J2004. 147: 582–6.
5.
DarouicheR.O.Treatment of infections associated with surgical implants. N Engl J Med2004; 350: 1422–9.
6.
SivaratnamK., DugganJ.M.Left ventricular assist device infections: Three case reports and a review of the literature. ASAIO J200248: 2–7.
7.
CabellC.H., JollisJ.G., PetersonG.E.Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med2002; 162: 90–4.
8.
Centers for Disease Control and Prevention (CDC).Staphylococcus aureus resistant to vancomycin – United States, 2002. MMWR Morb Mortal Wkly Rep2002; 51: 565–7.
9.
Centers for Disease Control and Prevention (CDC).Vancomycin-resistant Staphylococcus aureus – New York, 2004. MMWR Morb Mortal Wkly Rep2004; 53: 322–3.
10.
ChangS., SievertD.M., HagemanJ.C.Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med2003; 348: 1342–7.
11.
LiuY., AmesB., GorovitsE.SdrX, a serine-aspartate repeat protein expressed by Staphylococcus capitis with collagen VI binding activity. Infect Immun2004; 72: 6237–44.
12.
CucarellaC.Expression of the biofilm-associated protein interferes with host protein receptors of Staphylococcus aureus and alters the infective process. Infect Immun2002; 70: 3180–6.
13.
O'ConnellD.P., NanavatyT., McDevittD., GurusiddappaS., HookM., FosterT.J.The fibrinogen-binding MSCRAMM (clumping factor) of Staphylococcus aureus has a Ca2+-dependent inhibitory site. J Biol Chem1998; 273: 6821–9.
14.
PattiJ.M., House-PompeoK., BolesJ.O., GarzaN., GurusiddappaS., HookM.Critical residues in the ligand-binding site of the Staphylococcus aureus collagen-binding adhesin (MSCRAMM). J Biol Chem1995; 270: 12005–11.
15.
Schwarz-LinekU., PlevinM.J., PickfordA.R., HookM., CampbellI.D., PottsJ.R.Binding of a peptide from a Streptococcus dysgalactiae MSCRAMM to the N-terminal F1 module pair of human fibronectin involves both modules. FEBS Lett2001; 497: 137–40.
16.
JohD., SpezialeP., GurusiddappaS., ManorJ., HookM.Multiple specificities of the staphylococcal and streptococcal fibronectin-binding microbial surface components recognizing adhesive matrix molecules. Eur J Biochem1998; 258: 897–905.
17.
SpezialeP., JohD., VisaiL.A monoclonal antibody enhances ligand binding of fibronectin MSCRAMM (adhesin) from Streptococcus dysgalactiae. J Biol Chem1996; 271: 1371–8.
18.
SillanpaaJ., XuY., NallapareddyS.R., MurrayB.E., HookM.A family of putative MSCRAMMs from Enterococcus faecalis. Microbiology2004; 150: 2069–78.
19.
NallapareddyS.R., WeinstockG.M., MurrayB.E.Clinical isolates of Enterococcus faecium exhibit strain-specific collagen binding mediated by Acm, a new member of the MSCRAMM family. Mol Microbiol2003; 47: 1733–47.
20.
WolzC., GoerkeC., LandmannR., ZimmerliW., FluckigerU.Transcription of clumping factor A in attached and unattached Staphylococcus aureus in vitro and during device-related infection. Infect Immun2002; 70: 2758–62.
21.
Colque-NavarroP., PalmaM., SoderquistB., FlockJ.I., MollbyR.Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: Clumping factor and an extracellular fibrinogen binding protein. Clin Diagn Lab Immunol2000; 7: 14–20.
22.
SibooI.R., CheungA.L., BayerA.S., SullamP.M.Clumping factor A mediates binding of Staphylococcus aureus to human platelets. Infect Immun2001; 69: 3120–7.
23.
Stutzmann MeierP., EntenzaJ.M., VaudauxP., FrancioliP., GlauserM.P., MoreillonP.Study of Staphylococcus aureus pathogenic genes by transfer and expression in the less virulent organism Streptococcus gordonii. Infect Immun2001; 69: 657–64.
24.
QueY.A., HaefligerJ.A., FrancioliP., MoreillonP.Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector. Infect Immun2000; 68: 3516–22.
25.
MoreillonP., EntenzaJ.M., FrancioliP.Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun1995; 63: 4738–43.
26.
LuongT.T., LeeC.Y.Overproduction of type 8 capsular polysaccharide augments Staphylococcus aureus virulence. Infect Immun2002; 70: 3389–95.
27.
WattsA., KeD., WangQ., PillayA., Nicholson-WellerA., LeeJ.C.Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun2005; 73: 3502–11.
28.
NilssonI.M., PattiJ.M., BremellT., HookM., TarkowskiA.Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus mediated septic death. J Clin Invest1998; 101: 2640–9.
29.
JosefssonE., HartfordO., O'BrienL., PattiJ.M., FosterT.Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis2001; 184: 1572–80.
30.
BrouilletteE., LacasseP., ShkretaL.DNA immunization against the clumping factor A (ClfA) of Staphylococcus aureus. Vaccine2002; 20: 2348–57.
31.
ShkretaL., TalbotB.G., DiarraM.S., LacasseP.Immune responses to a DNA/protein vaccination strategy against Staphylococcus aureus induced mastitis in dairy cows. Vaccine2004; 23: 114–26.
32.
FlockM., FlockJ.I.Rebinding of extracellular adherence protein Eap to Staphylococcus aureus can occur through a surface-bound neutral phosphatase. J Bacteriol2001; 183: 3999–4003.
LeeJ., ParkJ., ShepherdS.Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun1997; 65: 4146–51.
35.
NemethJ., LeeJ.C.Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis. Infect Immun1995; 63: 375–80.
36.
TollersrudT., ZernichowL., AndersenS.R., KennyK., LundA.Staphylococcus aureus capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle. Vaccine2001; 19: 3896–903.
37.
MaJ., CocchiaroJ., LeeJ.C.Evaluation of serotypes of Staphylococcus aureus strains used in the production of a bovine mastitis bacterin. J Dairy Sci2004; 87: 178–82.
38.
DomanskiP.J., PatelP.R., BayerA.S.Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus. Infect Immun2005; 73: 5229–32.
39.
ReilleyS.W.E., ReynoldsL., BennettB., PattiJ.M., HetheringtonS.Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers. Antimicrob Agents Chemother2005; 49: 959–62.
40.
BloomB.T., KueserT.J., OelbergD.G., BifanoE.M., WhiteR.D., SchelonkaR.L., PearlmanS.A., HetheringtonS.V.A Phase 1 multicenter study and tolerance of a donor-selected staphylococcal immune globulin in very low birth weight infants. Pediatric Academic Societies Annual Meeting 2003. Seattle, Washington. Abstract 1804.
41.
BloomB., SchelonkaR., KueserT.Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J2005; 24: 858–66.
42.
BurnieJ.P., MatthewsR.C., CarterT., BeaulieuE., DonohoeM., ChapmanC., WilliamsonP., HodgettsS.J.Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infec Immun2000; 68: 3200–9.
